CPBIO Holding Company Limited Issues Profit Warning for 1H2026
Key Highlights for Investors
- Significant Drop in Profit Expected: CPBIO Holding Company Limited has issued a profit warning, announcing that it expects a consolidated profit attributable to shareholders of approximately US\$9.5 million for the six months ended 30 June 2026 (1H2026). This represents a sharp decline compared to the US\$17.0 million recorded in the same period last year (1H2025).
- Main Cause – Slowdown in Animal Farming: The company attributes the decrease in profit primarily to a slowdown in the animal farming sector in China, which has negatively impacted its chlortetracycline and animal health businesses.
- Timing of Results Announcement: The company is still in the process of preparing its unaudited consolidated results for 1H2026 and expects to release the official results in mid-August 2026.
- Advisory to Shareholders and Investors: The board advises shareholders and potential investors to exercise caution when dealing in the shares of the company, given the expected decline in profit.
- Information Status: The profit warning is based on preliminary information currently available to the company and may be subject to change once the unaudited results are finalized.
Details and Implications for Shareholders
This announcement is a material event and likely to be price sensitive. The anticipated decrease in profit—over 44% compared to the prior year’s interim period—signals challenges in CPBIO’s operating environment, especially in its core animal health and pharmaceutical segments. The slowdown in China’s animal farming sector has directly affected demand for key products such as chlortetracycline, a widely used antibiotic in livestock production.
Given the scale of the profit decrease and the broad impact on the company’s core business lines, this development could lead to volatility in CPBIO’s share price. Investors should closely monitor subsequent disclosures from the company, as the final unaudited results may provide additional insights into the company’s performance and outlook.
The board’s explicit caution to shareholders and potential investors underlines the uncertainty and the need for careful consideration before making any trading decisions.
Board of Directors
As of the date of the announcement, the board comprises:
- Mr. Soopakij Chearavanont (Chairman and Executive Director)
- Mr. Thirayut Phityaisarakul (Executive Director)
- Mr. Nopadol Chiaravanont (Executive Director)
- Mr. Chawalit Na Muangtoun (Executive Director)
- Ms. Kobboon Srichai (Non-executive Director)
- Mr. Yoichi Ikezoe (Non-executive Director)
- Mr. Surasak Rounroengrom (Independent Non-executive Director)
- Mr. Cheng Yuk Wo (Independent Non-executive Director)
- Mr. Edward Ko Ming Tung (Independent Non-executive Director)
- Ms. Cheung Marn Kay (Independent Non-executive Director)
The announcement was authorized by Mr. Chawalit Na Muangtoun, Director, in Hong Kong on 22 July 2026.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are urged to exercise caution and consult with their financial advisors before making any investment decisions. The information is based on preliminary disclosures by CPBIO Holding Company Limited and may change when the final interim results are released.
